中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

477 records (took 0.039 seconds)

    ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS
    342.
    发明申请
    ARSENIC-BASED TREATMENT OF CANCERS AND INFLAMMATORY DISORDERS 审中-公开
    基于ARSENIC的癌症治疗和炎症性疾病

    公开(公告)号：US20160184356A1

    公开(公告)日：2016-06-30

    申请号：US14776929

    申请日：2014-03-14

    Applicant: Ke Jian Jim LIU ,  Laurie HUDSON ,  Karen COOPER ,  Xixi ZHOU ,  STC.UNM

    Inventor： Ke Jian Jim Liu ,  Laurie Hudson ,  Karen Cooper ,  Xixi Zhou

    IPC: A61K33/36 ,  A61K45/06 ,  A61K41/00

    CPC classification number: A61K33/36 ,  A61K31/166 ,  A61K31/407 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/454 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/55 ,  A61K31/555 ,  A61K31/7068 ,  A61K41/0038 ,  A61K45/06 ,  A61N2005/1098 ,  A61K2300/00

    Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from a cancer (particularly a chemotherapeutic or radiotherapeutic-resistant cancer) or from an inflammatory disorder, the method comprising co-administering to the subject a pharmaceutically-effective amount of: (a) one or more elements or compounds selected from the group consisting of arsenic, an arsenite and arsenic trioxide (ATO); and optionally (b) at least one anticancer agent (preferably a DNA damaging agent); and/or (c) at least one or more Poly(ADP-ribose) polymerase (PARP) inhibitors other than arsenic, an arsenite and arsenic trioxide (ATO). In preferred embodiments, the arsenic for the treatment of cancer, arsenite and ATO serve as radio sensitizers for concomitant radiotherapy as well as PARP inhibitors. Methods for treating inflammatory disease are also disclosed. Related pharmaceutical formulations are also provided.

    Abstract translation: 在一个实施方案中，本发明提供了治疗患有癌症（特别是化学治疗或放射治疗耐药性癌症）或炎症性疾病的受试者的方法，所述方法包括向受试者共同施用药物有效量的： （a）选自砷，亚砷酸钠和三氧化二砷（ATO）中的一种或多种元素或化合物; 和（b）至少一种抗癌剂（优选DNA损伤剂）; 和/或（c）至少一种或多种除砷以外的聚（ADP-核糖）聚合酶（PARP）抑制剂，亚砷酸钠和三氧化二砷（ATO））。 在优选实施方案中，用于治疗癌症，亚砷酸盐和ATO的砷用作伴随放射治疗的放射敏化剂以及PARP抑制剂。 还公开了治疗炎性疾病的方法。 还提供了相关的药物制剂。

    Rab7 GTPase inhibitors and related methods of treatment
    343.
    发明授权
    Rab7 GTPase inhibitors and related methods of treatment 有权
    Rab7 GTPase抑制剂及相关治疗方法

    公开(公告)号：US09376452B2

    公开(公告)日：2016-06-28

    申请号：US14278468

    申请日：2014-05-15

    Applicant: STC.UNM ,  UNIVERSITY OF KANSAS

    Inventor： Angela Wandinger-Ness ,  Larry Sklar ,  Jacob Agola ,  Zurab Surviladze ,  Jeffrey Aube ,  Jennifer Golden ,  Chad E. Schroeder ,  Denise S. Simpson

    IPC: C07D495/04 ,  A61K31/381 ,  A61K45/06

    CPC classification number: C07D495/04 ,  A61K31/381 ,  A61K45/06

    Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.

    Abstract translation: 本发明涉及化合物及其作为Rab7 GTPase的抑制剂或活化剂的用途，用于治疗或预防Rab 7 GTP酶相关疾病如神经病变，癌症，骨骼和脂质储存代谢疾病的发生。 本发明也适用于Rab7灭活或其蛋白质 - 蛋白质相互作用被调节以促进病原体的细胞内存活的感染性疾病。 所描述的化合物作为核苷酸结合的竞争性抑制剂，因此也可用作靶向其他小GTP酶的支架。 一方面，本发明的治疗方法用于治疗或预防遗传性感觉神经病发作，例如Charcot-Marie-Tooth 2B型疾病。 还提供了相关的药物组合物，测定和药物筛选。

    3D TISSUE MODEL FOR SPATIALLY CORRELATED ANALYSIS OF BIOCHEMICAL, PHYSIOLOGICAL AND METABOLIC MICRO-ENVIRONMENTS
    344.
    发明申请
    3D TISSUE MODEL FOR SPATIALLY CORRELATED ANALYSIS OF BIOCHEMICAL, PHYSIOLOGICAL AND METABOLIC MICRO-ENVIRONMENTS 审中-公开
    用于生物化学，生理和代谢微环境的空间相关分析的3D组织模型

    公开(公告)号：US20160178618A1

    公开(公告)日：2016-06-23

    申请号：US14973303

    申请日：2015-12-17

    Applicant: STC.UNM

    Inventor： James P. Freyer ,  Andrew P. Shreve ,  Jacqueline DeLora

    IPC: G01N33/50 ,  G01N33/574 ,  C12M1/00 ,  C12M1/34 ,  C12M3/00

    CPC classification number: C12M29/10 ,  C12M21/08 ,  C12M25/14 ,  C12M35/08 ,  C12M41/26 ,  C12M41/32 ,  C12M41/34 ,  C12M41/38 ,  C12M41/46

    Abstract: Disclosed is a perfusion device and methods of use including a generally cylindrical body and a packed bed of nanosensor-cell embedded matrix spheres (nanoCEMS) disposed between layers of inert microspheres. A concentration of a molecule of interest can be established within the perfusion device to effect the cellular and chemical microenvironment of the nanoCEMS, the nanoCEMS in turn creating their own concentration gradients nutrients and waste products in response, which can be measured by nanosensors. The collected measurements can be applied to a transport model to calculate concentrations of various molecules at discreet locations in the perfusion chamber. Also disclosed is a method for making nanoCEMS by mixing a polymeric mixture with a crosslinking solution and dispersed through a nested dispensing device such that mixing of the two mixtures occurs in air. A piezoelectric transducer coupled to the dispensing device controls the droplet formation rate.

    Abstract translation: 公开了一种灌注装置和使用方法，包括设置在惰性微球体层之间的纳米传感器 - 电池嵌入式基质球（nanoCEMS）的大体圆柱体和填充床。 可以在灌注装置内建立一个关注分子的浓度，以实现nanoCEMS的细胞和化学微环境，nanoCEMS反过来又产生了自己的浓度梯度营养物质和废物，这可以通过纳米传感器测量。 所收集的测量值可应用于运输模型，以计算灌注腔中谨慎位置处各种分子的浓度。 还公开了通过将聚合物混合物与交联溶液混合并通过嵌套分配装置分散来制备nanoCEMS的方法，使得两种混合物在空气中混合。 耦合到分配装置的压电换能器控制液滴形成速率。

    SYSTEM AND METHODS FOR MANAGING CONGESTIVE HEART FAILURE
    345.
    发明申请
    SYSTEM AND METHODS FOR MANAGING CONGESTIVE HEART FAILURE 审中-公开
    用于管理心绞痛失败的系统和方法

    公开(公告)号：US20160171174A1

    公开(公告)日：2016-06-16

    申请号：US14907426

    申请日：2014-08-15

    Applicant: STC.UNM

    Inventor： Glen H. Murata

    IPC: G06F19/00 ,  G06F17/30

    CPC classification number: G06F16/283 ,  G16H10/20 ,  G16H50/20 ,  G16H50/70

    Abstract: The invention is a multi-purpose system and methods that focuses on the prevention of congestive heart failure (CHF) exacerbations by identifying the population at risk, examining their use of medications that optimize ventricular function, tracking weight changes through different phases of illness, and retrieving vital sign and laboratory data needed for treatment intensification.

    Abstract translation: 本发明是一种多用途系统和方法，其重点是通过识别处于危险中的人群来预防充血性心力衰竭（CHF）恶化，检查其使用优化心室功能的药物，通过不同疾病阶段跟踪体重变化，以及 检索治疗强化所需的生命体征和实验室数据。

    System and methods for usage management in multi-level security networks
    346.
    发明授权
    System and methods for usage management in multi-level security networks 有权
    多级安全网络中的使用管理系统和方法

    公开(公告)号：US09270701B1

    公开(公告)日：2016-02-23

    申请号：US13871250

    申请日：2013-04-26

    Applicant: STC.UNM

    Inventor： Christopher C. Lamb ,  Gregory L. Heileman

    IPC: G06F17/00 ,  H04L29/06

    CPC classification number: H04L63/20 ,  H04L63/0227

    Abstract: A system and methods for transferring information between two or more incompatible security domains or levels of classification by embedding policy-centric content management components into an information-centric network. Specifically, overlay architectures enable cloud computing for multi-level security environments.

    Abstract translation: 通过将以策略为中心的内容管理组件嵌入到以信息为中心的网络中，在两个或多个不兼容的安全域或分级级别之间传送信息的系统和方法。 具体来说，覆盖架构可以实现多层次安全环境的云计算。

    SYSTEM AND METHODS FOR DYNAMIC MANAGEMENT OF HARDWARE RESOURCES
    349.
    发明申请
    SYSTEM AND METHODS FOR DYNAMIC MANAGEMENT OF HARDWARE RESOURCES 有权
    硬件资源动态管理系统与方法

    公开(公告)号：US20150309802A1

    公开(公告)日：2015-10-29

    申请号：US14791627

    申请日：2015-07-06

    Applicant: STC.UNM

    Inventor： Marios Stephanou Pattichis ,  Yuebing Jiang ,  Daniel Rolando Llamocca Obregon

    IPC: G06F9/44 ,  H04N19/625 ,  G06F17/50

    CPC classification number: G06F9/4401 ,  G06F17/5054 ,  G06F2217/08 ,  H03H17/0241 ,  H03H17/0294 ,  H03H17/06 ,  H04N19/625

    Abstract: A dynamically reconfigurable framework manages processing applications in order to meet time-varying constraints to select an optimal hardware architecture. The optimal architecture satisfies time-varying constraints including for example, supplied power, required performance, accuracy levels, available bandwidth, and quality of output such as image reconstruction. The process of determining an optimal solution is defined in terms of multi-objective optimization using Pareto-optimal realizations.

    Abstract translation: 动态可重构框架管理处理应用程序，以便满足时变约束以选择最佳硬件体系结构。 最优架构满足时变约束，包括例如所提供的功率，所需性能，精度水平，可用带宽以及诸如图像重建的输出质量。 确定最优解的过程是使用帕累托最优实现的多目标优化来定义的。

Patent Agency Ranking